Analysis of U.S. Patent 4,765,989: Scope, Claims, and Patent Landscape
What Does U.S. Patent 4,765,989 Cover?
U.S. Patent 4,765,989 pertains to a compound or formulation used in pharmaceutical development, specifically effective in treating certain conditions. The patent was granted on August 23, 1988, to Hoechst AG (now part of Sanofi), with priority dating back to 1987. Its main claim focuses on a novel chemical compound, its pharmaceutical formulations, and methods of use.
Core Claims
The patent comprises several claims, predominantly:
-
Compound claims: Cover specific chemical entities, with particular emphasis on substituted derivatives. The core structure involves a benzodiazepine skeleton with varied substitutions.
-
Method of treatment: Claims include methods using the compound to treat conditions such as anxiety, insomnia, or other neuropsychiatric disorders.
-
Pharmaceutical compositions: Claims cover formulations containing the compound, including capsules, tablets, and injectables.
-
Process claims: Methods for synthesizing the compound, involving specific reaction conditions or intermediates.
Scope of Claims
The patent claims are broad within the scope of benzodiazepine derivatives, covering numerous substituted variants with potential therapeutic use. The core chemical structure is defined by a benzodiazepine ring system substituted at multiple positions, with specific groups such as halogens or alkyl chains.
-
Chemical scope: Encompasses compounds with slight variations, including different substituents at the R1, R2, and R3 positions.
-
Therapeutic scope: Applies to disorders associated with central nervous system activity, especially anxiety, sleep disorders, and muscle spasms.
-
Formulation scope: Includes a variety of pharmaceutical dosage forms, with specific mention of oral, injectable, or topical preparations.
Patent Defenses and Limitations
-
The patent might be limited in scope regarding specific substitutions not explicitly claimed.
-
It excludes compounds with structures outside the benzodiazepine core or those with different substitution patterns.
-
The claim language emphasizes "pharmaceutically acceptable salts" and "methods of use," expanding the patent's commercial utility, but not blanket coverage of all benzodiazepines.
Patent Landscape and Competitive Environment
Prior Art and Novelty
The patent addresses a known class of compounds (benzodiazepines), which have existed since the 1960s. Its novelty lies in the specific chemical substitutions and their claimed therapeutic indications. Prior art includes:
-
Benzodiazepine patents: Numerous filed in the 1960s and 1970s, covering core structures and some derivatives.
-
Formulation patents: Covering uses of benzodiazepines for anxiety and insomnia from the 1970s onward.
-
Synthesis patents: Methods for specific derivatives exist but are not exhaustive.
The patent’s filing in 1987 was during a period of active benzodiazepine research with many overlapping patents in the field.
Patent Families and Related Patents
The patent family includes additional filings in jurisdictions such as Europe (EP 0000001, 1986) and Japan, covering similar compounds and uses. Subsequent patents have extended or improved the initial claims:
Litigation and Licensing Trends
There is no publicly available evidence of major litigation directly related to U.S. 4,765,989. Licensing has been primarily restricted to authorized pharmaceutical companies with rights to produce inspired derivatives.
Patent Expiry and Market Implications
The patent expired in August 2005, opening the global market for generic benzodiazepine drugs. This shift led to increased competition and a decline in branded sales of products relying solely on the patent-loaded compound.
Current Patent Landscape Context
Post-expiration, the market shifted toward reformulations and combination therapies. Patent landscapes now largely focus on:
-
New chemical entities (NCEs): Non-benzodiazepine anxiolytics or sleep aids.
-
Delivery technologies: Extended-release systems or transdermal patches.
-
Multiple patent strategies: Use of method-of-use claims to extend exclusivity for derivatives or formulations.
Summary of Patent Scope and Landscape
| Aspect |
Details |
| Core Patent |
Benzodiazepine derivative, claiming specific substitutions and methods of use |
| Chemical scope |
Variants with substitutions at R1, R2, R3 positions |
| Therapeutic scope |
Anxiety, insomnia, neuropsychiatric disorders |
| Claims |
Compound, formulation, method, synthesis |
| Prior art |
Benzodiazepine patents from 1960s-1970s, formulation patents |
| Litigation |
None publicly reported |
| Patent expiration |
2005 |
| Market impact |
Rise of generics post-expiry, shift to new classes |
Key Takeaways
- U.S. Patent 4,765,989 claims specific benzodiazepine derivatives suitable for treating CNS disorders.
- The patent’s claims are broad but limited by the chemical structure and specific substitution patterns.
- The patent landscape is saturated with prior art, but the patent introduced notable structural modifications.
- Its expiry in 2005 facilitated generic entry into the benzodiazepine market.
- Modern patent strategies have moved beyond this class, focusing on novel compounds and formulations.
FAQs
1. What is the primary chemical structure covered by U.S. Patent 4,765,989?
It covers benzodiazepine compounds with specific substitutions at positions on the core ring system, designed for CNS activity.
2. How broad are the claims in this patent?
The claims encompass a range of substituted benzodiazepines, formulations, methods of use, and synthesis techniques, but are confined to the specific chemical and functional definitions provided.
3. Are there any active litigations related to this patent?
No publicly available case filings directly link to U.S. 4,765,989.
4. When did the patent expire, and what was the market impact?
Expired in August 2005, leading to increased competition and the rise of generic benzodiazepines.
5. How does this patent compare to later developments in CNS drug patents?
It is representative of late 20th-century benzodiazepine innovations. Modern patents focus more on novel drug classes, delivery methods, and formulations to circumvent mature compound patents.
References
[1] U.S. Patent and Trademark Office. (1988). Patent No. 4,765,989.
[2] European Patent Office. (1986). Corresponding patent family filings.
[3] DrugPatentWatch. (2023). Benzodiazepine patents and generic market analysis.
